Cardamon

Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT

Maintenance Summary Form

Patient Initials	
Trial Number	C A R -

(This form has 3 pages including cover sheet)

Please send forms to:

Cardamon Trial Coordinator
CR UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London W1T 4TJ

General enquires: **020 7679 9860**Randomisations: **020 7679 9860** between 9.00am and 5.00pm
Fax: **020 7679 9861**

E-mail: ctc.cardamon@ucl.ac.uk





Cancer Research UK and UCL Cancer Trials Centre



Cancer Research UK and UCL Cancer Trials Centre



Additional instructions for completing forms

Page 2 of 3

The maintenance summary form collects details of the patient's maintenance treatment.

Specific Fields

- Total number of Maintenance cycles should be entered—even if a patient completed only 1 day of a cycle, it is considered a cycle
- Maintenance summary form should be completed at the end of the Maintenance treatment phase. If a patient withdraws at any time during maintenance, the maintenance form detailing the last cycle the patient received should be submitted to the UCL CTC concurrently with this form

Completing forms

- Ensure all entries are clear, legible and written in black ink
- Avoid the use of abbreviations and acronyms
- Do not leave any fields blank. In case of missing data
 - ND (not done) if a test has not been performed or a measure not taken. If applicable state the reason
 - NA (not applicable) if a measure if not required
 - NK (not known) if data is unknown. This should only be used once every effort to obtain the data has been exhausted.
- CRFs may only be completed by an appropriately qualified individual delegated as responsible by the PI on the site delegation log
- CRF Footer section
 - The "completed by" Name should be legible
 - Each CRF should be signed and dated by the person completing the form
 - Do not complete the UCL CTC Use only section
- The CRF should be sent/faxed to the Cancer Trials Centre (CTC) with a copy retained at the Site (ensure when photocopying the page that the copy is added to the CRF booklet in the same place where the original was stored)

If you have any questions about how to complete this form please contact the Cardamon Trial Coordinator on: 020 7679 9860



Cancer Research UK and UCL Cancer Trials Centre




_			_				
~	_	_	_	_		_	-
	а			а	m	О	n

Trial Number

CA





Patient		
Initials		

Maintenance Summary Form

Page 3 of 3

To be completed for all patients

Did patient receive full maintenance t	1= Yes, please complete this section only 2= No, please complete both sections
Total number of Carfilzomib maintenar	nce treatment cycles received:
Date treatment stopped/completed:	D D M M Y Y Y
Specify a reason for discontinuation or	not completing maintenance treatment: (choose one option only from below)
1 = Disease Progression / Relapse (Pleas	e complete a Progression/Relapse form)
2 = Death (Please complete a Death form	n)
3 = Toxicity , please specify: (Please complete an AE/SAE form as app	ropriate)
4 = Lost to follow up (Please complete a	Lost to Follow up/ Withdrawal form)
5 =Intercurrent illness preventing furthe	r treatment, please specify:
6 =Other, please specify:	
Name of person completing form:	Signature of person completing form: Date completed:
The site PI or delegated investigator must sign to co	
nvestigator name:	Investigator signature: Date completed: D D M M Y Y Y Y